Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INKT 
Mink Therapeutics Inc (INKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: INKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $39
1 Year Target Price $39
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.86% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.32M USD | Price to earnings Ratio - | 1Y Target Price 39 |
Price to earnings Ratio - | 1Y Target Price 39 | ||
Volume (30-day avg) 3 | Beta 0.33 | 52 Weeks Range 4.56 - 76.00 | Updated Date 10/12/2025 |
52 Weeks Range 4.56 - 76.00 | Updated Date 10/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -105.19% | Return on Equity (TTM) -1238.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 73748882 | Price to Sales(TTM) - |
Enterprise Value 73748882 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.67 | Shares Outstanding 4522927 | Shares Floating 1531961 |
Shares Outstanding 4522927 | Shares Floating 1531961 | ||
Percent Insiders 65.97 | Percent Institutions 1.37 |
Upturn AI SWOT
Mink Therapeutics Inc
Company Overview
History and Background
Mink Therapeutics, Inc. was a clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer. Founded in 2017, it emerged from research at the Baylor College of Medicine. In May 2024, the company announced it would discontinue development of its iNKT platform and wind down operations.
Core Business Areas
- iNKT Cell Therapy Development: Focused on engineering iNKT cells to target specific cancer antigens. They engineered cells to express specific receptors to target cancer cells directly
Leadership and Structure
Jennifer Wu, MD, served as Chief Executive Officer. The company had a scientific advisory board and a board of directors overseeing its operations. Operations are being wound down in 2024
Top Products and Market Share
Key Offerings
- INTACT: INTACT was Mink's iNKT cell therapy platform targeting solid tumors and hematological malignancies. Due to a lack of efficacy, trials were stopped and the company's iNKT platform discontinued.
Market Dynamics
Industry Overview
The cell therapy market is a growing field with significant potential for cancer treatment. It is highly competitive with many companies developing cell-based therapies targeting a variety of cancers.
Positioning
Mink Therapeutics aimed to be a leader in iNKT cell therapy. The company ceased operations due to lack of clinical efficacy.
Total Addressable Market (TAM)
The cell therapy market is estimated to reach hundreds of billions of dollars. Given the company's discontinuation of iNKT platfrom due to lack of efficacy trials, the company is currently not in a position to address the TAM.
Upturn SWOT Analysis
Strengths
- Innovative iNKT cell therapy platform
Weaknesses
- Limited clinical data
- Cash Burn
- Small company size
- Discontinuation of INKT Platform in 2024
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of iNKT cell therapy platform to other diseases
Threats
- Competition from other cell therapy companies
- Regulatory hurdles
- Clinical trial failures
- Market adoption of cell therapies
Competitors and Market Share
Key Competitors
- CRSP
- BLUE
- CAR T-cell therapy companies
Competitive Landscape
Mink faced strong competition from established cell therapy companies and CAR T-cell therapy companies. Given discontinuation, Mink's therapies have no competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: The company showed limited growth as its main therapy platform was discontinued
Future Projections: No future growth projections are available as the company is winding down operations.
Recent Initiatives: None, the company ceased operations
Summary
Mink Therapeutics was a clinical-stage biotechnology company focused on innovative iNKT cell therapies. However, due to discontinuation of their iNKT platform, the company ceased all clinical trials and operations and is being wound down. This action has resulted in negative impacts on shareholder returns. As a result, Mink is no longer viable as a business.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Financial news sources
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mink Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-10-15 | President, CEO & Director Dr. Jennifer S. Buell Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://minktherapeutics.com |
Full time employees 23 | Website https://minktherapeutics.com | ||
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.